Obesity drugs & warnings
Regulators and industry moves are heating up: the FDA has approved Wegovy HD for weight management and Imcivree gained a label expansion for hypothalamic obesity — signaling more medical options entering practice (lqventures.com). At the same time India reports weight‑loss drug sales have jumped tenfold since 2021 to about $153 million annually, and health authorities are warning of misuse risks with cheap injections (freemalaysiatoday.com).
Wegovy HD’s approval came with a 7.2 mg once‑weekly semaglutide formulation and recorded a mean weight loss of about 20.7% at 72 weeks in the STEP UP trial. (novonordisk.mediaroom.com)) Novo Nordisk told investors it expects a U.S. launch of Wegovy HD in April 2026 and reported that roughly one in three trial participants on the 7.2 mg dose achieved 25% or greater weight loss. (novonordisk.mediaroom.com)) The FDA cleared Wegovy HD 54 days after filing under the Commissioner’s National Priority Voucher pilot programme, marking it as the fourth product approved through that expedited pathway. (fda.gov)) Rhythm Pharmaceuticals’ IMCIVREE label expansion was supported by the Phase 3 TRANSCEND trial (N=142), which showed an 18.4% placebo‑adjusted BMI reduction at 52 weeks and led to an indication that includes adults and children aged 4 and older with acquired hypothalamic obesity. (markets.financialcontent.com)) Rhythm estimated the U.S. population eligible for the expanded IMCIVREE indication at about 10,000 patients, and the company’s shares moved higher on the approval amid analyst estimates that the opportunity could exceed $1 billion. (onyxnewsroom.com)) India’s core semaglutide patent expired on March 20, 2026, triggering plans by more than 40 domestic manufacturers to launch upward of 50 branded generics and driving reported annual sales of weight‑loss drugs to about US$153 million in 2026. (france24.com)) Indian regulators have stepped up inspections, warned drugmakers against direct or surrogate advertising of GLP‑1 products, and flagged risks from unauthorised sales at wellness clinics and online pharmacies as monthly generic injection prices range roughly between 1,300 and 4,200 rupees ($15–$45). (economictimes.indiatimes.com))
